Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
DOI: https://doi.org/10.2147/JIR.S393850
IF: 4.5
2023-03-11
Journal of Inflammation Research
Abstract:Yilun Lu, 1– 3, &ast Ding Li, 1– 3, &ast Yueyue Huang, 1– 3 Yuanyuan Sun, 1– 3 Hongmin Zhou, 1– 3 Fanrong Ye, 1– 3 Hongjing Yang, 1– 3 Tingting Xu, 1– 3 Shichao Quan, 3– 6 Jingye Pan 1– 5 1 Department of Intensive Care Unit, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China; 2 Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province, Wenzhou, People's Republic of China; 3 Wenzhou Key Laboratory of Critical Care and Artificial Intelligence, Wenzhou, People's Republic of China; 4 Collaborative Innovation Center for Intelligence Medical Education, Wenzhou, People's Republic of China; 5 Zhejiang Engineering Research Center for Hospital Emergency and Process Digitization, Wenzhou, People's Republic of China; 6 Department of General Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jingye Pan, Department of Intensive Care Unit, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China, Email Shichao Quan, Department of General Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China, Email Purpose: Sepsis is an aggressive and life-threatening organ dysfunction induced by infection. Excessive inflammation and coagulation contribute to the negative outcomes for sepsis, resulting in high morbidity and mortality. In this study, we explored whether Eupatilin could alleviate lung injury, reduce inflammation and coagulation during sepsis. Methods: We constructed an in vitro sepsis model by stimulating RAW264.7 cells with 1 μg/mL lipopolysaccharide (LPS) for 6 hours. The cells were divided into control group, LPS group, LPS+ Eupatilin (Eup) group, and Eup group to detect their cell activity and inflammatory cytokines and coagulation factor levels. Cells in LPS+Eup and Eup group were pretreated with Eupatilin (10μM) for 2 hours. In vivo, mice were divided into sham operation group, cecal ligation and puncture (CLP) group and Eup group. Mice in the CLP and Eup groups were pretreated with Eupatilin (10mg/kg) for 2 hours by gavage. Lung tissue and plasma were collected and inflammatory cytokines, coagulation factors and signaling were measured. Results: In vitro, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and tissue factor (TF) expression in LPS-stimulated RAW264.7 cells was downregulated by Eupatilin (10μM). Furthermore, Eupatilin inhibited phosphorylation of the JAK2/STAT3 signaling pathway and suppressed p-STAT3 nuclear translocation. In vivo, Eupatilin increased the survival rate of the mice. In septic mice, plasma concentrations of TNF-α, IL-1β and IL-6, as well as TF, plasminogen activator inhibitor 1 (PAI-1), D-dimer, thrombin-antithrombin complex (TAT) and fibrinogen were improved by Eupatilin. Moreover, Eupatilin alleviated lung injury by improving the expression of inflammatory cytokines and TF, fibrin deposition and macrophage infiltration in lung tissue. Conclusion: Our results revealed that Eupatilin may modulate inflammation and coagulation indicators as well as improve lung injury in sepsis via the JAK2/STAT3 signaling pathway. Keywords: Eupatilin, sepsis, inflammation, coagulation, JAK2/STAT3 Sepsis is a life-threatening organ dysfunction caused by infection, which results from dysregulated host response. 1 A study reported in Lancet showed that sepsis remains a major cause of health loss worldwide, with 48.9 million cases each year and approximately 11 million deaths, which accounts around one-fifth of the total global deaths. 2 According to Nature Reviews Disease Primers, more than half of sepsis patients are complicated with coagulation system imbalance. 3 Moreover, in patients who have sepsis with disseminated intravascular coagulation (DIC) the mortality rate is almost twice that of sepsis patients without DIC. 4 Therefore, reducing inflammation and coagulation disorders could be the key to reducing sepsis mortality. Macrophages are involved in various pathophysiological processes in sepsis, including inflammation, coagulation, immunity and metabolism, and play a crucial role in sepsis-induced acute lung injury. 5,6 In the early stages of sepsis, macrophages engulf pathogens and activate the innate immune system. Macrophages express pattern recognition receptors (PRRs), which can detect pathogen-associated molecular patterns (PAMPs) or damage-associated molec -Abstract Truncated-
immunology